• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconPharmaceutical Industry

Pharmaceutical Industry

Page 88 of 100
J. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc., waits for the start of their annual general meeting in Laval, Quebec
HealthValeant cuts ties to controversial pharmacy chain Philidor
By Geoffrey SmithOctober 30, 2015
Hedge fund manager Bill Ackman
FinanceAnother one of Bill Ackman’s top stocks is down 50%
By Jen WiecznerOctober 29, 2015
A Starbucks cafe in Sanlitun. For the third quarter of 2015
FeaturesPharma megadeal and Starbucks earnings — 5 things to know today
By Tom Huddleston Jr. and Geoffrey SmithOctober 29, 2015
Allergan Inc.'s Botox Cosmetic As Actavis Plc Buys Drugmaker For $66 Billion
HealthWhen Viagra met Botox: Pfizer, Allergan eye mega-merger
By Geoffrey SmithOctober 29, 2015
Cholesterol lowering pill
HealthThis drug will make your flu shot less effective
By TIMEOctober 29, 2015
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
FinanceValeant accounting scandal: 4 critical questions that have been left unanswered
By Stephen GandelOctober 26, 2015
RetailWhy the drug price scandal won’t be enough to keep down prices
By Laura LorenzettiOctober 26, 2015
Imprimis Turing Drug
HealthThis company is offering a $1 alternative to Turing’s $750 drug
By Laura LorenzettiOctober 23, 2015
MSMB Capital Management CIO Martin Shkreli
HealthThis super-expensive drug is getting a $1 rival
By Benjamin SnyderOctober 23, 2015
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
FinanceValeant short seller on pharmacy alliance: It’s the ‘turd in the punch bowl’
By Stephen GandelOctober 22, 2015
J. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc., waits for the start of their annual general meeting in Laval, Quebec
FinanceValeant’s accounting problems: It gets worse
By Stephen GandelOctober 22, 2015
HealthBig pharma won’t stay silent in drug pricing debate for long
By Erika FryOctober 22, 2015
New Reasearch Shows That Aspirin May Cut Breast Cancer Risk
HealthThe world’s biggest clinical trial is for one of the cheapest drugs
By Claire GrodenOctober 22, 2015
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
FinanceForget the plunging stock price, here’s Valeant’s biggest problem
By Laura LorenzettiOctober 22, 2015
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
HealthShort-seller: Is Valeant the pharmaceutical Enron?
By Laura LorenzettiOctober 21, 2015
1...
  • 86
  • 87
  • 88
  • 89
  • 90
...100
Most Popular
Workplace Culture
Gen Z is dating less. The result is one of the most unprepared workforcesAn image of a popular article
By Jake AngeloMarch 15, 2026
Economy
Trump's immigration crackdown is backfiring by hurting the U.S.-born workers it was meant to help, data showsAn image of a popular article
By Sasha RogelbergMarch 10, 2026
Commentary
Ray Dalio: I've studied 500 years of history and fear we're entering the most dangerous phase of the 'Big Cycle'An image of a popular article
By Ray DalioMarch 14, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
Fortune Secondary Logo
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.